Ideaya Biosciences Inc - Asset Resilience Ratio
Ideaya Biosciences Inc (IDYA) has an Asset Resilience Ratio of 41.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Ideaya Biosciences Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Ideaya Biosciences Inc's Asset Resilience Ratio has changed over time. See IDYA net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Ideaya Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ideaya Biosciences Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $487.97 Million | 41.17% |
| Total Liquid Assets | $487.97 Million | 41.17% |
Asset Resilience Insights
- Very High Liquidity: Ideaya Biosciences Inc maintains exceptional liquid asset reserves at 41.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ideaya Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Ideaya Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Ideaya Biosciences Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Ideaya Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.66% | $591.94 Million | $1.12 Billion | -4.03pp |
| 2023-12-31 | 56.69% | $368.10 Million | $649.32 Million | -19.66pp |
| 2022-12-31 | 76.35% | $296.20 Million | $387.97 Million | +35.77pp |
| 2021-12-31 | 40.57% | $154.72 Million | $381.35 Million | -30.35pp |
| 2020-12-31 | 70.93% | $211.55 Million | $298.27 Million | +13.50pp |
| 2019-12-31 | 57.42% | $64.89 Million | $113.00 Million | -14.52pp |
| 2018-12-31 | 71.94% | $69.46 Million | $96.54 Million | +30.78pp |
| 2017-12-31 | 41.17% | $7.20 Million | $17.48 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methion… Read more